Education
About Us
Working with TipRanks
Follow Us
AbbVie (ABBV)
NYSE:ABBV
ABBV Stock Chart & Stats
$227.99
-$1.97(-1.10%)
At close: 4:00 PM EST
$227.99
-$1.97(-1.10%)
Day’s Range― - ―
52-Week Range$163.81 - $244.81
Previous CloseN/A
Volume1.02M
Average Volume (3M)6.14M
Market Cap
$403.22B
Enterprise Value$392.79B
Total Cash (Recent Filing)$6.47B
Total Debt (Recent Filing)$70.48B
Price to Earnings (P/E)108.6
Beta0.32
Next Earnings
Oct 31, 2025EPS Estimate
1.77Last Dividend Ex-Date
Oct 15, 2025Dividend Yield2.88%
Share Statistics
EPS (TTM)2.97
Shares Outstanding1,766,558,200
10 Day Avg. Volume5,192,182
30 Day Avg. Volume6,144,245
Financial Highlights & Ratios
PEG Ratio-6.08
Price to Book (P/B)94.54
Price to Sales (P/S)5.58
P/FCF Ratio17.63
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue6.73
Enterprise Value/Gross Profit9.07
Enterprise Value/Ebitda27.74
Forecast
1Y Price Target
$242.16Price Target Upside6.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceABBV has steadily delivered on high expectations throughout the year, on display again last quarter as 2Q25 earnings featured a textbook set of beat/raise results.
Patent And IP ProtectionAbbVie reached a settlement delaying generic competition for Rinvoq to 2037, extending its patent protection.
Product SuccessKey drivers Skyrizi and Rinvoq have consistently outperformed, beating Visible Alpha Consensus Data by an average of 3.5% and 4.7% respectively.
Bears Say
AbbVie News
ABBV FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was $163.81 and its highest was $244.81 in the past 12 months.
What is AbbVie’s market cap?
AbbVie’s market cap is $403.22B.
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Oct 31, 2025 which is in 4 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Jul 31, 2025. The company reported $2.97 earnings per share for the quarter, beating the consensus estimate of $2.88 by $0.09.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of $1.64 which represents an annual dividend yield of 2.88%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is 1.77.
How many shares outstanding does AbbVie have?
AbbVie has 1,766,558,200 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of $2.97 in its last earnings report, beating expectations of $2.88. Following the earnings report the stock price went down -0.154%.
Which hedge fund is a major shareholder of AbbVie?
Currently, no hedge funds are holding shares in ABBV
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$242.16 (6.22% Upside)
$242.16 (6.22% Upside)
Blogger Sentiment
Bullish
ABBV Sentiment 90%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 139.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.42%
12-Months-Change
Fundamentals
Return on Equity
112.90%
Trailing 12-Months
Asset Growth
-3.35%
Trailing 12-Months
Company Description
AbbVie
AbbVie Inc. is a global biopharmaceutical company that focuses on the research, development, and commercialization of advanced therapies for complex diseases. Established in 2013 as a spinoff from Abbott Laboratories, AbbVie operates primarily in the sectors of immunology, oncology, neuroscience, and virology. Its core products include the blockbuster drug Humira, which treats autoimmune conditions, as well as other therapies like Imbruvica for cancer and Rinvoq for inflammatory diseases. The company is dedicated to addressing unmet medical needs through innovation and scientific advancement.
ABBV Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong overall performance with significant achievements in revenue growth, pipeline advancement, and strategic acquisitions. However, challenges remain in specific segments such as HUMIRA sales and the aesthetics market.View all ABBV earnings summariesABBV Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
ABBV Stock 12 Month Forecast
Average Price Target
$242.16
▲(6.22% Upside)
Technical Analysis
Ownership Overview
0.07% Insiders
19.92% Mutual Funds
0.56% Other Institutional Investors
57.32% Public Companies and Individual Investors